Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models

Based on the author's recent experience, there appears to be some confusion regarding the steps required to qualify a systems pharmacology model as adequate for the intended purpose. This manuscript outlines the model evaluation approach used in the author's recent publication(1) on the sy...

Descripción completa

Detalles Bibliográficos
Autor principal: Agoram, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944115/
https://www.ncbi.nlm.nih.gov/pubmed/24552986
http://dx.doi.org/10.1038/psp.2013.77
_version_ 1782306332901113856
author Agoram, B
author_facet Agoram, B
author_sort Agoram, B
collection PubMed
description Based on the author's recent experience, there appears to be some confusion regarding the steps required to qualify a systems pharmacology model as adequate for the intended purpose. This manuscript outlines the model evaluation approach used in the author's recent publication(1) on the systems pharmacology of a 5-lipoxygenase inhibitor and is an attempt to generate discussion on this topic within the pharmacometrics and systems pharmacology community.
format Online
Article
Text
id pubmed-3944115
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-39441152014-03-06 Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models Agoram, B CPT Pharmacometrics Syst Pharmacol Perspective Based on the author's recent experience, there appears to be some confusion regarding the steps required to qualify a systems pharmacology model as adequate for the intended purpose. This manuscript outlines the model evaluation approach used in the author's recent publication(1) on the systems pharmacology of a 5-lipoxygenase inhibitor and is an attempt to generate discussion on this topic within the pharmacometrics and systems pharmacology community. Nature Publishing Group 2014-02 2014-02-19 /pmc/articles/PMC3944115/ /pubmed/24552986 http://dx.doi.org/10.1038/psp.2013.77 Text en Copyright © 2014 American Society for Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ CPT: Pharmacometrics and Systems Pharmacology is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Perspective
Agoram, B
Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
title Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
title_full Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
title_fullStr Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
title_full_unstemmed Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
title_short Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models
title_sort evaluating systems pharmacology models is different from evaluating standard pharmacokinetic–pharmacodynamic models
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944115/
https://www.ncbi.nlm.nih.gov/pubmed/24552986
http://dx.doi.org/10.1038/psp.2013.77
work_keys_str_mv AT agoramb evaluatingsystemspharmacologymodelsisdifferentfromevaluatingstandardpharmacokineticpharmacodynamicmodels

Ejemplares similares